---
figid: PMC9239340__fonc-12-924808-g001
figtitle: Epigenetic Mechanisms Influencing Therapeutic Response in Breast Cancer
organisms:
- Homo sapiens
- Rattus norvegicus
organisms_ner:
- Drosophila melanogaster
pmcid: PMC9239340
filename: fonc-12-924808-g001.jpg
figlink: /pmc/articles/PMC9239340/figure/f1/
number: F1
caption: Mechanism of action of classical and novel endocrine therapies. Schematic
  diagram depicting, on the left, the canonical estrogen receptor (ER) activating
  signaling cascade and potential downstream interactor types; and on the right, the
  different mechanisms of disruption of this signaling pathway upon distinct endocrine
  therapy strategies, such as, aromatase inhibitors (AI, 1), selective ER modulators
  (SERMs, 2), selective ER degraders (SERDs, 3) and proteolysis targeting chimeras
  (PROTACs, 4). E2, estrogen; ER, estrogen receptor; T, tamoxifen; F, fulvestrant;
  E3, E3 ligase; HMT, histone methyltransferase; HAT, histone acetyltransferase; coA/R,
  co-activator/repressor; PF, pioneer factor; TSS, transcription start site; ERE,
  estrogen response element.
papertitle: Epigenetic Mechanisms Influencing Therapeutic Response in Breast Cancer.
reftext: Amaia Arruabarrena-Aristorena, et al. Front Oncol. 2022;12:924808.
year: '2022'
doi: 10.3389/fonc.2022.924808
journal_title: Frontiers in Oncology
journal_nlm_ta: Front Oncol
publisher_name: Frontiers Media S.A.
keywords: breast cancer | epigenetics | estrogen receptor - ESR1 | endocrine therapy
  | transcription factor | chromatin regulation
automl_pathway: 0.9661048
figid_alias: PMC9239340__F1
figtype: Figure
redirect_from: /figures/PMC9239340__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9239340__fonc-12-924808-g001.html
  '@type': Dataset
  description: Mechanism of action of classical and novel endocrine therapies. Schematic
    diagram depicting, on the left, the canonical estrogen receptor (ER) activating
    signaling cascade and potential downstream interactor types; and on the right,
    the different mechanisms of disruption of this signaling pathway upon distinct
    endocrine therapy strategies, such as, aromatase inhibitors (AI, 1), selective
    ER modulators (SERMs, 2), selective ER degraders (SERDs, 3) and proteolysis targeting
    chimeras (PROTACs, 4). E2, estrogen; ER, estrogen receptor; T, tamoxifen; F, fulvestrant;
    E3, E3 ligase; HMT, histone methyltransferase; HAT, histone acetyltransferase;
    coA/R, co-activator/repressor; PF, pioneer factor; TSS, transcription start site;
    ERE, estrogen response element.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Coa
  - Cor
  - cort
  - cora
  - Crz
  - snf
  - hfw
  - Iswi
  - E3
---
